EP1957480A1 - Derive d'oxindole substitues, medicaments les contenant et leur utilisation - Google Patents

Derive d'oxindole substitues, medicaments les contenant et leur utilisation

Info

Publication number
EP1957480A1
EP1957480A1 EP06819882A EP06819882A EP1957480A1 EP 1957480 A1 EP1957480 A1 EP 1957480A1 EP 06819882 A EP06819882 A EP 06819882A EP 06819882 A EP06819882 A EP 06819882A EP 1957480 A1 EP1957480 A1 EP 1957480A1
Authority
EP
European Patent Office
Prior art keywords
group
general formula
methoxy
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06819882A
Other languages
German (de)
English (en)
Inventor
Thorsten Oost
Wilfried Lubisch
Wolfgang Wernet
Wilfried Hornberger
Liliane Unger
Hervé Geneste
Astrid Netz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Publication of EP1957480A1 publication Critical patent/EP1957480A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to novel substituted oxindole derivatives, medicaments containing them and their use for the treatment of diseases.
  • Vasopressin is an endogenous hormone that exerts various effects on organs and tissues. Vasopressin is related to oxytocin (OT), so that both peptides to a vasopressin / oxytocin family summarizes. It is believed that the vasopressin / oxytocin system plays a role in various disease states.
  • V1a, V1b and V3 and V2 receptors vasopressin receptors
  • OT receptor oxytocin receptor
  • Antagonists of these receptors in particular also antagonists which specifically bind only to one of the above receptors, represent new therapeutic approaches to the treatment of diseases (M. Thibonnier, Exp. Olpin Invest. Drugs 1998, 7 (5), 729-740 ). For example, it has been found that a selective antagonist of vasopressin V1 b receptor in
  • V1b receptor antagonists are useful for the treatment of emotional disorders or diseases, e.g. Stress, anxiety and / or depression, of particular interest.
  • novel substituted oxindoles which carry an arylsulfonyl group in the 1-position.
  • 1-phenyl-sulfonyl-1,3-dihydro-2H-indol-2-ones have already been described as ligands of the vasopressin receptors.
  • WO 93/15051, WO95 / 18105, WO 98/25901, WO 01/55130, WO 01/55134, WO 01/064668, WO 01/98295, WO05 / 021534 and WO05 / 030755 describe compounds which have been disclosed by US Pat Oxindol scaffold are derived and carry an arylsulfonyl group in 1-position. These compounds differ significantly in the substitution in the 3-position.
  • WO 93/15051 and WO 98/25901 describe 1-phenylsulfonyl-1,3-dihydro-2H-indol-2-one as ligands of vasopressin receptors in which the oxindole skeleton in the 3-position is represented by two alkyl radicals substituted, which may also be linked to a cycloalkyl radical (spiro linkage).
  • the spiro ring may contain heteroatoms such as oxygen and nitrogen (optionally with substituents).
  • WO 95/18105 describes 1-phenylsulfonyl-1,3-dihydro-2H-indol-2-one as ligands of the vasopressin receptors which carry a nitrogen substituent in the 3-position.
  • a radical is attached, which is selected from alkyl, cycloalkyl, phenyl and benzyl (each optionally with substituents).
  • WO 03/008407 describes 1-phenylsulfonyloxindoles in which pyridylpiperazines are bonded to the oxindole in the 3-position via an oxycarbonyl group.
  • the object of the present invention is to provide further compounds for the treatment or prophylaxis of various vasopressin-dependent diseases.
  • the compounds should have advantages over known compounds, such as improved metabolic stability and / or improved pharmacological activity.
  • the benefits may be demonstrated using, for example, suitable models that allow prognosis for the desired application in the treatment of patients.
  • A is an aromatic, heteroaromatic, partially aromatic or partially heteroaromatic mono- or bi-cyclic ring having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms as ring members, which additionally contains 0, 1, 2, 3 or 4 identical or different hetero atoms independently selected from the group consisting of nitrogen, oxygen and sulfur, which may contain as ring members and which is substituted with the radical R a 1 and also with one, two or three radicals R A 11 , R A 12 and / or R A 13 may be substituted independently of one another and independently of their occurrence from the group consisting of bromine, chlorine, fluorine, CN, CF 3 , OCF 3 , OCHF 2 , OH, O-C 1 -C 4 -alkyl and C 1 -C 4 -alkyl;
  • R A 1 is selected from the group consisting of
  • Ci-C4-alkylene-R A 2 Co-C3 alkylene-0-C2-C4-alkylene-R A 2, C 0 -C 3 alkylene NR A 3 -C 2 -C 4 -alkylene R is A 2 ;
  • R A 3 is selected from the group consisting of hydrogen and C 1 -C 4 alkyl
  • R A 2 is selected from the group consisting of
  • R A 4 is independently of its occurrence selected from the group consisting of the respective individual residues
  • R A 5 is selected from the group consisting of hydrogen, hydroxy and optionally substituted C 1 -C 4 -alkyl; such as hydroxy-C 1 -C 4 -alkyl, in particular hydrogen and C 1 -C 4 -alkyl;
  • B is an aromatic, heteroaromatic, partially aromatic or partially heteroaromatic mono- or bicyclic ring having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms as ring members, which is additionally 0 , 1, 2, 3 or 4 identical or different heteroatoms, independently selected from the group consisting of nitrogen, oxygen and sulfur, may contain as ring members and which may be substituted by one, two or three radicals R B 1 , R B 2 and / or R B 3 , wherein R B 1 , R B 2 and R B 3 are independently and independently of their respective
  • Occurs selected from the group consisting of chlorine, bromine, fluorine, CN, CF 3 , OCF 3 , OCHF 2 , OH, O-Ci-C 4 alkyl and Ci-C 4 alkyl;
  • R 1 is selected from the group consisting of hydrogen, bromine, chlorine, fluorine, iodine, CN, CF 3 , OCF 3 , OCHF 2 , O-C 1 -C 4 -alkyl, C 1 -C 4 -alkyl,
  • Ci-C 4 alkenyl and C 2 -C 4 alkynyl Ci-C 4 alkenyl and C 2 -C 4 alkynyl
  • R 2 is selected from the group consisting of hydrogen, C 1 -C 4 -alkyl,
  • R Y 1 is selected from the group consisting of hydrogen and C 1 -C 4 alkyl
  • R Y 2 is selected from the group consisting of hydrogen, phenyl, C 1 -C 6 -alkyl and C 3 -C 7 -cycloalkyl,
  • R ⁇ 1 and R ⁇ 2 are also taken together, together with the atom to which they are attached, to form a 4-, 5-, 6- or 7-membered, saturated or unsaturated carbocyclic ring containing a nitrogen atom containing one or two substituents R ⁇ 6 and / or R ⁇ 7 have each independently and independently of their occurrence may be selected from the group consisting of fluoro, OH, OC 1 -C 4 alkyl, phenyl and C 1 -C 4 alkyl; or in the case of adjacent position to each other R ⁇ 6 and R 7 together with the respective carbon atom to which they are attached, can form a fused substituted or unsubstituted benzene ring;
  • R ⁇ 3 is selected from the group consisting of hydrogen and methyl
  • R ⁇ 4 is a saturated, partially saturated or unsaturated ring having 1, 2, 3, 4, 5, or 6 C atoms as ring members, which additionally 1, 2, 3 or 4 identical or different heteroatoms, independently selected from Group consisting of nitrogen, oxygen and sulfur, which may contain as ring members and which may be substituted by one or two radicals R ⁇ 8 and / or R ⁇ 9 , wherein R ⁇ 8 and R ⁇ 9 are independently selected and independently of their occurrence are selected from the group consisting of chlorine, bromine, fluorine, CN, OH, C 1 -C 4 alkyl and C 1 -C 4 alkyl;
  • the invention therefore relates to compounds of the formula (I), their tautomers, their prodrugs and in particular their physiologically tolerated salts.
  • a preferred embodiment of the present invention relates to compounds of the general formula (I) as described above or in claim 1, their tautomers, their prodrugs and their physiologically tolerable salts, wherein the variables A, R A 1 , R A 2 , RA 3 , RA 4 , RA 5 , B, R 1 , R 2 , Y, R Y 1 , R Y 2 , R Y 3 and R ⁇ 4 independently of one another and preferably in combination have the following meanings:
  • A is a ring selected from the group consisting of benzene, Benzo [1, 3] dioxole, thiophene and pyridine, which is substituted with the radical R A 1 and may be additionally substituted in addition with one or two radicals R A 11 and / or R A 12 , independently of one another and independently of their respective occurrence are selected from the group consisting of chlorine, fluorine, hydroxy, methoxy, ethoxy, propoxy, methyl, ethyl and propyl;
  • R A 1 is selected from the group consisting of
  • R A 3 is selected from the group consisting of hydrogen and C 1 -C 4 alkyl
  • R A 2 is selected from the group consisting of
  • R A 4 is independently of its occurrence selected from the group consisting of the respective individual residues
  • R A 5 is selected from the group consisting of hydrogen and C 1 -C 4 alkyl
  • R B is an aromatic or heteroaromatic mono- or bicyclic ring having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms as ring members, the additionally 0, 1, 2, 3 or 4 identical or different hetero atoms independently selected from the group consisting of nitrogen, oxygen and sulfur, which may contain as a ring member and with one or two radicals R B 1 and / or R B 2 may be substituted, wherein R B 1 and R B 2 are independently selected from the group consisting of chlorine, fluorine, CN, OH, O-Ci-C 4 alkyl and dC 4 alkyl;
  • R 1 is selected from the group consisting of hydrogen, chlorine, fluorine,
  • R 2 is selected from the group consisting of hydrogen, chlorine, fluorine and methyl
  • R ⁇ 1 is selected from the group consisting of
  • R Y 2 is selected from the group consisting of hydrogen, phenyl and C 1 -C 4 -alkyl;
  • R ⁇ 1 and R ⁇ 2 are also taken together, together with the respective atom to which they are bonded, to form a 5- or 6-membered saturated or unsaturated carbocyclic ring containing a nitrogen ring atom which may have a substituent R ⁇ 6 selected from is selected from the group consisting of C 1 -C 4 -alkyl, O-Ci-C 4 -alkyl, fluorine and OH;
  • R Y 3 is hydrogen
  • R ⁇ 4 is a 5-membered or 6-membered heteroaromatic ring having 1, 2, 3, 4 or 5 C atoms as ring members which additionally has 1, 2, 3 or 4 identical or different heteroatoms, independently selected from the group, consisting of nitrogen, oxygen and sulfur, containing as ring member and which may optionally be substituted with a radical R ⁇ 8 , wherein R ⁇ 8 is selected independently of the occurrence of the group consisting of C 1 -C 4 alkyl.
  • a particularly preferred embodiment relates to compounds of general formula (I) as described above or in claim 1 or 2, wherein
  • A is a benzene ring which is substituted with the radical R A 1 and may additionally be substituted by a radical R A 11 ;
  • R A 1 1 is selected from the group consisting of chloro, fluoro, methoxy, ethoxy, propoxy, methyl and ethyl;
  • R A 1 is a radical selected from the group consisting of the respective individual radicals / ⁇ M - H / ⁇ M / C r C 4 - ⁇ kyl ⁇ x / C 1 -C 4 -alkyl * N * N * N * N
  • B is a ring selected from the group consisting of benzene, pyridine,
  • Thiophene and quinoline each of which may be substituted with 1 or 2 radicals R B 1 and / or R B 2 , wherein R B 1 and R B 2 are independently selected from the group consisting of chlorine, fluorine, CN, methyl Ethyl, hydroxy, methoxy and ethoxy;
  • R 1 is selected from the group consisting of hydrogen, chlorine, fluorine, CN, methoxy and methyl;
  • R 2 is selected from the group consisting of hydrogen, chlorine and fluorine
  • Y is a radical selected from the group consisting of the respective individual radicals
  • R Y 4 is a radical selected from the group consisting of pyridine,
  • R ⁇ 6 is selected from the group consisting of the radicals
  • a preferred embodiment relates to compounds of general formula (I) as described above or in any one of claims 1 to 3, wherein
  • A is selected from the group consisting of the respective individual residues
  • R A 1 is a radical selected from the group consisting of the respective individual radicals
  • B is a ring selected from the group consisting of the respective individual radicals
  • R B 1 and R B 2 are independently and independently selected from the group consisting of hydrogen, chlorine, fluorine, CN, methyl, methoxy and ethoxy;
  • R 1 is selected from the group consisting of chlorine, fluorine, methoxy and CN;
  • R 2 is selected from the group consisting of hydrogen, chlorine and fluorine
  • Y is selected from the group consisting of the respective individual radicals
  • R Y 4 is selected from the group consisting of the respective individual radicals
  • a particularly preferred embodiment relates to compounds of general formula (I) as described above or in any one of claims 1 to 4, wherein
  • A is a radical selected from the group consisting of the respective individual radicals
  • R A 1 is a radical selected from the group consisting of the respective individual residues
  • B is a radical selected from the group consisting of the respective individual radicals
  • R 1 is selected from the group consisting of chlorine, fluorine, and CN;
  • R 2 is selected from the group consisting of hydrogen, chlorine and fluorine
  • Y is a radical selected from the group consisting of the respective individual radicals
  • a very particularly preferred embodiment relates to compounds of general formula (I) as described above or in any of claims 1 to 5, wherein
  • A is a radical selected from the group consisting of the respective individual radicals
  • R A 1 is a radical selected from the group consisting of the respective individual radicals
  • R 1 is selected from the group consisting of chlorine and CN;
  • R 2 is selected from the group consisting of hydrogen and chlorine
  • Y is a radical selected from the group consisting of the respective individual radicals
  • a particularly preferred embodiment relates to compounds of the general formula (I) as described above or in any one of claims 1 to 6, wherein the radicals A, B, Y, R 1 and R 2 each independently have one of the meanings given above and wherein the radical R 2 is bonded to the 6-position of the oxindole ring skeleton, and also tautomeric forms, prodrugs and, in particular, physiologically tolerable salts of compounds of the formula (I).
  • a particularly preferred embodiment relates to compounds of the abovementioned general formula (I), in which the radicals A, B, R 1 and R 2 each independently of one another have the meanings given above or in claims 1 to 8, and
  • mixtures of enantiomeric and diastereomeric forms of the compounds of the formula (I) which comprise as main constituent compounds of the formula (I) whose Y radicals have the stereochemistry shown here.
  • Another particularly preferred embodiment relates to compounds of the abovementioned general formula (I), in which the radicals A, B, R 1 and R 2 each independently of one another have the meanings given above or in claims 1 to 8, and
  • mixtures of enantiomeric and diastereomeric forms of the compounds of the formula (I) which comprise as main constituent compounds of the formula (I) whose Y radicals have the stereochemistry shown here.
  • Another particularly preferred embodiment relates to compounds of the abovementioned general formula (I), in which the radicals A, B, R 1 and R 2 each independently of one another have the meanings given above or in claims 1 to 8, and Y for the rest
  • mixtures of enantiomeric and diastereomeric forms of the compounds of the formula (I) which comprise as main constituent compounds of the formula (I) whose Y radicals have the stereochemistry shown here.
  • a further particularly preferred embodiment relates to compounds of the abovementioned general formula (I), in which the radicals A, B, R 1 and R 2 may each independently of one another have the meanings given above or in claims 1 to 8, and
  • mixtures of enantiomeric and diastereomeric forms of the compounds of the formula (I) which comprise as main constituent compounds of the formula (I) whose Y radicals have the stereochemistry shown here.
  • a very particularly preferred embodiment of the present invention relates to compounds of the general formula (Ia), wherein the radicals R 1 , R 2 , RA 2 , RA 1 1 , RB 1 , RY 1 and R ⁇ 2 have one of the meanings given above and wherein X is O or S, preferably O,
  • radicals A, B, Y, R 1 and R 2 are each independently one of the meanings given above and in which the radical Y on the C atom which carries the radical R y 4 , the S configuration and the carbon atom in the position 3 of the oxindol-2-one skeleton either the (R) - or the ( S) configuration, as well as tautomeric forms, prodrugs and in particular physiologically acceptable salts of compounds of the formula (I) or (Ia).
  • At least one compound of the general formula (I) or (La) as described above or according to any one of claims 1 to 16 for use as a medicament there is provided at least one compound of the general formula (I) or (La) as described above or according to any one of claims 1 to 16 for use as a medicament.
  • composition containing at least one compound of the general formula (I) or (La) as described above or in any one of claims 1 to 17.
  • the use of at least one compound of the general formula (I) or (La) as described above or according to one of claims 1 to 16 for the treatment and / or prophylaxis of at least one disease is selected the group consisting of hypertension, pulmonary hypertension, heart failure, myocardial infarction, coronary spasm, unstable angina, PTCA (percutaneous transluminal coronary angioplasty), ischemia of the heart, disorders of the renal system, edema, renal vasospasm, necrosis of the renal cortex, hyponatremia, hypokalemia, Schwartz-Bartter syndrome, disorders of the gastrointestinal tract, gastric vasospasm, hepatocirrhosis, gastric and intestinal ulcer, emesis, emesis occurring in chemotherapy, and / or motion sickness and / or for the manufacture of a medicament for the treatment and / or prophylaxis of at least one of the said diseases , provided.
  • PTCA percutaneous transluminal coronary angioplasty
  • the use of at least one compound of the general formula (I) or (La) as described above according to one of claims 1 to 16 for the treatment of sleep disorders and / or for the preparation of a medicament for the treatment of sleep disorders provided.
  • a method for the treatment and / or prophylaxis of at least one disease is selected from the group consisting of diabetes insipidus, nocturnal enuresis, incontinence, diseases in which blood coagulation disorders occur and delaying voiding in a patient in that an effective amount of at least one compound of the general formula (I) or (LA) described above or according to one of Claims 1 to 16 is administered to the patient.
  • a method for the treatment and / or prophylaxis of at least one disease is selected from the group consisting of hypertension, pulmonary hypertension, heart failure, myocardial infarction, coronary spasm, unstable angina, PTCA (percutaneous transluminal coronary angioplasty), ischemia of the heart, disorders of the renal system, edema, renal vasospasm, necrosis of the renal cortex, hyponatremia, hypokalaemia, Schwartz-Bartter syndrome, disorders of the gastrointestinal tract, gastric vasospasm, hepatocirrhosis, gastric and intestinal ulcer, emesis, emesis arising in chemotherapy, and Motion sickness in a patient, characterized in that the patient is administered an effective amount of at least one compound of the general formula (I) or (La) as described above or according to one of claims 1 to 16.
  • a method for the treatment and / or prophylaxis of affective disorders in a patient characterized in that the patient an effective amount of at least one compound of general formula (I) or (La), as above or according to any one of claims 1 to 16, is provided.
  • a method of treating anxiety disorders and / or stress dependent Anxiety disorders in a patient characterized in that the patient is administered an effective amount of at least one compound of the general formula (I) or (La) as described above or according to one of claims 1 to 16.
  • a method for treating memory impairment and / or Alzheimer's disease in a patient characterized in that the patient an effective amount of at least one compound of general formula (I) or (La), as above or according to any one of claims 1 to 16, is provided.
  • a method for treating psychosis and / or psychotic disorders in a patient characterized in that the patient an effective amount of at least one compound of general formula (I) or (La), as above or according to any one of claims 1 to 16, is provided.
  • a method for treating Cushing's syndrome in a patient characterized in that the patient an effective amount of at least one compound of general formula (I) or (La), as above or according to one of Claims 1 to 16 are administered.
  • a method for the treatment of sleep disorders in a patient characterized in that the patient an effective amount of at least one compound of general formula (I) or (La), as above or according to one of claims 1 to 16 described.
  • a method of treating depressive disorders in a patient in that the patient is provided with an effective amount of at least one compound of the general formula (I) or (La) as described above or according to one of Claims 1 to 16.
  • a method of treating and / or preventing vasomotor symptoms and / or thermoregulatory dysfunctions, such as the hot flush symptom, in a patient is characterized by providing the patient with an effective amount of at least one of A compound of the general formula (I) or (La) as described above or according to any one of claims 1 to 16 is administered.
  • a method for the treatment and / or prophylaxis of schizophrenia and / or psychosis, in a patient is characterized in that the patient is provided with an effective amount of at least one compound of the general formula (I) or (La) , as described above or according to any one of claims 1 to 16, is provided.
  • a process for the preparation of at least one compound of the general formula (I) or (La) as described above or according to one of claims 1 to 16 is characterized in that it has been prepared by the person skilled in the art Knowledge of the technical teaching according to the invention in execution and / or in an analogous version of known method steps can be produced provided.
  • a further preferred embodiment relates to compounds of the general formula (I) or (La) as described above, characterized in that they have a selectivity to the vasopressin receptor subtype V1b against at least one of the closely related vasopressin / oxytocin receptor subtypes (for example vasopressin V1a, vasopressin V2 and / or oxytocin).
  • a further preferred embodiment relates to compounds of the general formula (I) or (La) as described above, characterized in that they have improved metabolic stability.
  • the metabolic stability of a compound can be measured, for example, by incubating a solution of this compound with liver microsomes from certain species (for example, rat, dog or human) and determining the half-life of the compound under these conditions (RS Obach, Curr Opin Drug Discov Devel. 2001, 4, 36-44). It can be concluded from greater half-lives on improved metabolic stability of the compound. Stability in the presence of human
  • Liver microsomes are of particular interest as they allow prediction of metabolic degradation of the compound in the human liver. Compounds with increased metabolic stability (measured in the liver microsome test) are therefore likely to degrade more slowly also in the liver. The slower metabolic degradation in the liver can lead to higher and / or longer-lasting concentrations (effective levels) of the compound in the body, so that the elimination half-life of the compounds according to the invention is increased. Increased and / or longer lasting levels of activity may result in better efficacy of the compound in the treatment or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases.
  • improved metabolic stability can lead to increased bioavailability after oral administration, as the compound undergoes less metabolic degradation in the liver (so-called "first pass effect") after absorption in the intestine.An increased oral bioavailability may be due to increased concentration (level of action ) of the compound lead to a better efficacy of the compound after oral administration.
  • a further preferred embodiment relates to compounds of the general formula (I) or (La) as described above, characterized in that they are available in patients or relevant animal models which allow prognostic statements for use in the treatment compared to those of the prior art Technically known oxindole compounds, have improved pharmacological activity.
  • a further preferred embodiment relates to compounds of the general formula (I) selected from the group consisting of the examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 listed below, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90 and 91, and tautomeric forms, prodrugs and in particular physiologically acceptable salts, and non-salt forms of Compounds of the formula (I). Particularly preferably, the abovementioned compounds are provided in
  • a further preferred embodiment relates to compounds of the general formula (I) or (La) selected from the compounds of Examples 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103 listed below , 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128 , 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153 , 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171,
  • the compounds according to the invention can be present as a mixture of diastereomers or as a mixture of diastereomers in which one of the two diastereomers is enriched or as essentially diastereomerically pure compounds (diastereomeric excess of> 90%).
  • the compounds are present as substantially diastereomerically pure compounds.
  • the respective diastereomers may, in turn, be present as a mixture of enantiomers (for example as a racemate), as a mixture of enantiomers in which one of the two enantiomers is enriched, or as substantially enantiomerically pure compounds (enantiomeric excess ee> 90%).
  • the respective diastereomers are present as substantially enantiomerically pure compounds.
  • Particularly preferred are compounds that are substantially diastereomerically pure and enantiomerically pure (> 90%, ee> 90%).
  • Physiologically acceptable salts in the sense of the description, unless stated otherwise, can be formed, for example, with the following anions:
  • alkyl For the purposes of the present description, unless stated otherwise, the terms “alkyl”, “cycloalkyl”, “alkoxy”, “haloalkyl”, “alkenyl”, “alkynyl” or “alkylene” and radicals derived therefrom always include both unbranched and branched alkyl, cycloalkyl, alkoxy, haloalkyl, alkenyl, alkynyl or alkylene.
  • Ci-C ⁇ -alkyl and Ci-C 4 -alkyl in the sense of the description, unless otherwise stated, mean an optionally substituted straight-chain or branched saturated hydrocarbon chain with the respective number of carbon atoms from 1 to 6 or from 1 to 4 carbon atoms, such as methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1, 1-dimethylethyl, pentyl, 1-methylbutyl, 2-methyl-butyl, 1, 2-dimethylpropyl, 1 , 1-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1-methylpentyl, 1, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2,3-dimethylbutyl, 1, 1-dimethylbutyl, 2.2 Dimethylbutyl, 3,3-dimethylbutyl, 1,1,2-trimethylpropyl,
  • C 1 -C 4 -alkyl is preferably methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl or t-butyl.
  • d-Ce-alkoxy or "-O-Ci-C 6 -alkyl” means in the sense of the description, unless otherwise stated, an oxygen-bound optionally substituted Ci-C ⁇ -alkyl group, as above is defined.
  • C 3 -C 7 -cycloalkyl in the sense of the description, unless stated otherwise, means an optionally substituted saturated hydrocarbon ring having 3 to 7 ring members, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
  • dC 6 -haloalkyl or dC 4 -haloalkyl is, in the context of the description, unless otherwise stated, an optionally substituted one
  • C 2 -C 6 -alkenyl in the sense of the description, unless stated otherwise, means an optionally substituted branched or unbranched hydrocarbon chain containing at least one double bond having 2 to 6 carbon atoms.
  • C 2 -C 6 alkenyl contains one or two double bonds, most preferably one double bond.
  • Alkenyl groups are those as mentioned above for alkyl, which groups contain one or two double bonds, such as vinyl, 2-propenyl, 2-butenyl, 3-butenyl, 1-methyl-2-propenyl, 2-methyl-2 -propenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl 3-butenyl, 3-methyl-3-butenyl, 1, 1-dimethyl-2-propenyl, 1, 2-dimethyl-2-propenyl, 1-ethyl-2-propenyl, 2-hexenyl, 3-hexenyl, 4 -Hexenyl, 5-hexenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 3-methyl-3-pentenyl, 4-methyl 3-pentenyl
  • C 2 -C 6 -alkynyl the purposes of the description, unless stated otherwise, an optionally substituted branched or unbranched hydrocarbon chain containing at least one triple bond having 2 to 6 carbon atoms.
  • C 2 -C 6 alkynyl contains one or two triple bonds, most preferably a triple bond.
  • alkynyl groups are those as mentioned above for alkyl, which groups contain one or two triple bonds, such as ethynyl, 1-propynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-3-butynyl , 2-methyl-3-butynyl, 1-methyl-2-butynyl, 1, 1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl , 1-methyl-2-pentynyl, 1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 1-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3 Methyl 4-pentynyl, 4-methyl-2-pentynyl, 1,1-dimethyl
  • 3- to 10-membered carbocycle or “4 to 7-membered carbocyclic ring” or “carbocyclic ring having 2 to 10 C-atoms” mean in the sense of the description, unless stated otherwise, an optionally substituted saturated or completely or partially unsaturated hydrocarbon ring having 3 to 10 carbon atoms or 4 to 7 carbon atoms or 2-10 C atoms as ring atoms, such as cyclopropyl, cyclobutyl , Cyclopentyl, cyclohexy, cycloheptyl, cyclooctyl, cyclononyl or cyclodecanyl.
  • the carbocyclic ring may also contain heteroatoms as ring atoms.
  • the heteroatom ring members may optionally be included in place of the C-atom ring members or in addition to the C-atom ring members.
  • Halogen is, in the sense of the description, unless otherwise stated, a halogen atom selected from fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine, more preferably fluorine or chlorine.
  • C 1 -C 6 -haloalkyl or "C 1 -C 4 -haloalkyl” in the sense of the description, unless stated otherwise, denote an optionally substituted alkyl radical as defined above which is partially or completely independent of one another by one or more identical or different radicals selected from the group consisting of fluoro, chloro, bromo and iodo, eg CH 2 F, CHF 2 , CF 3 , CH 2 Cl, 2-fluoroethyl, 2-chloroethyl, 2,2,2-trifluoroethyl.
  • substituents in the sense of the description and the terms “substituted”, “optionally substituted” and “in each case unsubstituted or substituted ", unless stated otherwise, include: halogen, CN, CF 3 , CHF 2 , OCF 3 , OCHF 2 , NO 2 , NH 2 , OH, COOH, in each case branched or unbranched, optionally substituted C 1 -C 6 -alkyl , C 3 -C 7 -cycloalkyl, C 1 -C 6 -alkylene-O-C 1 -C 6 -alkyl or C 1 -C 6 -thioalkyl, O-C 1 -C 4 -alkyl, N (C 1 -C 4 -alkyl) 2 , NH (C 1 -C 4 -alkyl), aryl, -O-aryl, C 1 -C 4 -alkylene-O-aryl, NHCO-C
  • parenthesized expressions with subscripts are understood to mean, unless otherwise stated, that the meanings of the radicals in parentheses may be the same or different.
  • N (C 1 -C 4 -alkyl ky I) 2 in accordance with the description for N (Ci-C4 alkyl) (Ci-C 4 alkyl), wherein the two residues (Ci-C 4 alkyl) may be the same or different.
  • the symbol () represents a single bond which, if bound to a center of chirality, is intended to mean that the corresponding compound is denoted either as an approximately 1: 1 mixture (Racemat, (R / S) form) of the two enantiomeric forms with respect to the center of chirality or as separate (R) -enantiomers and / or (S) -enantiomers with respect to the center of chirality.
  • (CH 2 ) i, 2 means that the parenthetical expression occurs once or twice.
  • aromatic, heteroaromatic, partially aromatic or teilheteroaromatischer mono- or bicyclic ring means in the sense of the description, unless otherwise stated, a mono-or bicylic ring of carbon atoms (“aromatic” or “partially aromatic”) or a Combination of C and heteroatoms (“heteroaromatic” or “partially heteroaromatic”) is constructed in each case as ring members and an aromatic number of double bondings in the ring ("monocyclic") or in the two rings (“bicyclic") (“aromatic or "heteroaromatic") or only in one of the rings (“partially aromatic” or “partially heteroaromatic”).
  • aromatic rings examples include phenyl, naphthyl, fluorenyl, indenyl and phenanthrenyl, with phenyl and naphthyl, which may be 1-naphthyl or 2-naphthyl, being preferred. Most preferred is phenyl.
  • heteroaromatic rings are 2-furyl, 3-furyl, 2-pyrrolyl, 3-pyrrolyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thiazolyl, 4-thiazolyl, 5 Thiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 6-pyrimidyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 3-isothiazolyl, 4-isothiazolyl , 5-isothiazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 3-isoxazolyl, 4-isoxazolyl, 5-isothiazolyl, 2-imi
  • partially aromatic rings are: 5,6,7,8-tetrahydro-naphthalen-1-yl, 5,6,7,8-tetrahydro-naphthalen-2-yl, and indan-4-yl, indan-5 yl.
  • Examples of partially heteroaromatic rings are: benzo [1,3] dioxol-4-yl, benzo [1,3] dioxol-5-yl, 2,3-dihydro-benzo [1,4] dioxin-5-yl, and 2,3-dihydrobenzo [1, 4] dioxin-6-yl.
  • saturated or completely or partially unsaturated carbocyclic ring or “saturated or unsaturated carbocyclic ring” in the meaning of the description, unless otherwise stated, mean a ring formed from C atoms and optionally one or more heteroatoms or formed ring system, the has no double bond present in the ring ("saturated") or one or more conjugated or unconjugated or partially conjugated double bonds (“partially or completely unsaturated” or “unsaturated”) .
  • the carbocyclic ring may be a mono-, bi- or tricyclic ring
  • a bicyclic or tricyclic saturated carbocycle may, unless stated otherwise, be a bicycloalkyl or tricycloalkyl radical having 2 to 10 carbon atoms In a tricycloalkyl
  • the ring system preferably contains from 6 to 10, more preferably from 6 to 10, carbon atoms. Examples of a bicycloalkyl group include indanyl, camphyl and norborn
  • the compounds according to the invention are administered by different routes (for example intravenously, intramuscularly, orally) after administration, especially orally, effectively.
  • the present invention also provides the use of the compounds of the invention for the treatment and / or prophylaxis of diseases in which the course of the disease depends, at least in part, on vasopressin, i. Diseases that show an elevated vasopressin level, which may contribute indirectly or indirectly to the clinical picture.
  • the present invention provides the use of the compounds according to the invention for the treatment and / or prophylaxis of diseases such as diabetes insipidus, nocturnal enuresis, incontinence, diseases in which blood clotting disorders occur and / or delaying the voiding.
  • diseases such as diabetes insipidus, nocturnal enuresis, incontinence, diseases in which blood clotting disorders occur and / or delaying the voiding.
  • the present invention also provides the use of the compounds of the invention for the treatment and / or prophylaxis of the following diseases: hypertension, pulmonary hypertension, heart failure, myocardial infarction, coronary spasm, unstable angina, PTCA (percutaneous transluminal coronary angioplasia), ischemia of the heart, disorders of the renal system, edema, renal vasospasm, necrosis of the renal cortex, hyponatremia, hypokalaemia, Schwartz-Bartter syndrome, gastrointestinal disturbances, gastric vasospasm, hepatocirrhosis, gastric and intestinal ulcer, emesis, vomiting on chemotherapy, and motion sickness.
  • diseases hypertension, pulmonary hypertension, heart failure, myocardial infarction, coronary spasm, unstable angina, PTCA (percutaneous transluminal coronary angioplasia), ischemia of the heart, disorders of the renal system, edema, renal vasospasm, necrosis of the renal cortex,
  • the compounds of the present invention may also be used to treat various vasopressin-dependent disorders having central nervous causes or changes in the hypothalamic pituitary adrenal axis (HPA), for example, affective disorders such as depressive disorders and bipolar disorders. These include, for example, dythymous disorders, phobias, post-traumatic stress disorder, general anxiety disorders, panic disorders, seasonal depression and sleep disorders. Likewise, the compounds of the invention can be used for the treatment of anxiety disorders and stress-related anxiety disorders, such as generalized anxiety disorders, phobias, post-traumatic anxiety disorders, panic anxiety disorders, obsessive-compulsive
  • HPA hypothalamic pituitary adrenal axis
  • anxiety disorders acute stress-related anxiety disorders and social phobia.
  • the compounds of the invention can also be used for the treatment of memory disorders, Alzheimer's disease, psychosis, psychotic disorders, sleep disorders and / or the Cushing syndrome and all stress-dependent diseases.
  • the present invention also relates to pharmaceutical compositions containing an effective dose of a compound of the invention or a pharmaceutically acceptable salt thereof and suitable pharmaceutical carriers (excipients).
  • excipients are chosen according to the pharmaceutical form and the desired mode of administration.
  • the compounds of the general formula (I) according to the invention or optionally suitable salts of these compounds can be used for the preparation of pharmaceutical compositions for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, intratracheal, intranasal, transdermal or rectal administration and animals in uniform Administration forms mixed with conventional pharmaceutical carriers for the prophylaxis or treatment of the above disorders or diseases.
  • the suitable unitary dosage forms include forms for oral administration such as tablets, gelatin capsules, powders, granules and oral solutions or suspensions, forms for sublingual, buccal, intratracheal or intranasal administration, aerosols, implants, forms of subcutaneous, intramuscular or intravenous administration and forms of rectal administration.
  • the compounds of the invention can be used in creams, ointments or lotions.
  • the dose of the active principle may vary between 0.01 and 50 mg per kg body weight and per day.
  • Each unit dose may contain from 0.05 to 5000 mg, preferably from 1 to 1000 mg, of the active ingredient in combination with a pharmaceutical carrier. This unit dose can be administered 1 to 5 times a day, so that a daily dose of 0.5 to 25000 mg, preferably 1 to 5000 mg, is administered.
  • a solid composition is prepared in the form of tablets, the main ingredient is mixed with a pharmaceutical carrier such as gelatin, starch, lactose, magnesium stearate, talc, silica or the like.
  • a pharmaceutical carrier such as gelatin, starch, lactose, magnesium stearate, talc, silica or the like.
  • the tablets may be coated with sucrose, a cellulose derivative or other suitable substance or otherwise treated to have sustained or delayed activity and to continuously release a predetermined amount of the active principle.
  • a preparation in the form of gelatin capsules is obtained by mixing the active ingredient with an extender and incorporating the resulting mixture into soft or hard gelatin capsules.
  • a preparation in the form of a syrup or elixir or for administration in the form of drops may contain active ingredients together with a sweetening agent which is preferably calorie-free, methylparaben or propylparaben as antiseptics, a flavoring agent and a suitable coloring matter.
  • a sweetening agent which is preferably calorie-free, methylparaben or propylparaben as antiseptics, a flavoring agent and a suitable coloring matter.
  • the water-dispersible powders or granules may contain the active ingredients mixed with dispersants, wetting agents or suspending agents, such as polyvinylpyrrolidones, as well as sweeteners or flavoring agents.
  • Rectal administration is achieved by using suppositories prepared with binders which melt at rectal temperature, for example cocoa butter or polyethylene glycols.
  • Parenteral administration is effected using aqueous suspensions, isotonic saline solutions or sterile and injectable solutions containing pharmacologically acceptable dispersants and / or wetting agents, for example, propylene glycol or polyethylene glycol.
  • the active principle may also be formulated as microcapsules or centrosomes, if appropriate with one or more carriers or additives.
  • compositions according to the invention may contain other active principles which may be useful for the treatment of the above-mentioned disorders or diseases.
  • the present invention thus further relates to pharmaceutical compositions in which several active principles are present together, at least one of which is a compound of the invention.
  • the preparation of the oxindoles according to the invention can, for example, on the in the synthetic schemes 1.A and 1.B outlined path.
  • the variables have the same meanings as in the general formula (I) or (La).
  • the 3-hydroxyoxindoles (VI) can be prepared by adding lithium-organic or Grignard compounds to the 3-keto group of the substituted isatin V in an ethereal solvent such as THF.
  • THF ethereal solvent
  • the lithium species can be obtained from the iodo-aryl compound IV by treatment with organolithium reagents, such as n-butyllithium, in THF at low temperatures.
  • the corresponding Grignard compound can be prepared by treatment with magnesium in an ethereal solvent such as THF.
  • the cyclic acetal (IV) can be prepared in two stages (methylation of phenol-oxygen followed by protection of the aldehyde as acetal) from commercially available 3-hydroxy-4-iodobenzaldehyde (II).
  • the isomeric building block protected aldehyde function para to the methoxy group
  • the building blocks with protected aldehyde function which is used for the synthesis of compounds of the invention may be in the 2-position of the phenyl ring A fluorine, ethoxy or methyl as the radical R A 11 carry.
  • metallated heteroaromatics bearing a protected formyl group may be reacted in an analogous manner (protecting the formyl function as a cyclic acetal followed by lithium-halogen exchange or insertion of magnesium into the heteroaryl-halo - Bond) are produced, eg from commercially available 2-bromo-4-formyl-3-methoxypyridine, 6-bromo-2-formylpyridine, 5-bromo-3-formylpyridine, 2-bromo-4-formylpyridine, 2-bromo-5-formylpyridine, 4-bromo 2-formylthiophene, 3-bromo-2-formylthiophene, 5-bromo-2-formylthiophene or 3-bromo-4-formylthiophene.
  • radical A in the general formula (I) is a 2-methoxy-pyridin-3-yl radical
  • the aldehyde can be brominated ortho to the methoxy group (European Journal of Medicinal Chemistry (1977), 12 (6), 531-6) and the 5-bromo-6-methoxypyridine-3-carbaldehyde thus obtained subsequently as cyclic acetal to be protected.
  • the lithium-organic species obtained by lithium-halogen exchange with butyllithium can be added to substituted islets in the manner described above.
  • the 3-hydroxy-oxindoles (VI) can be converted into the compounds (VII) which have a
  • Leaching group LG wear in the 3-position are transferred, wherein the leaving group LG usual leaving groups, such as halides, mesylate or tosylate, may be.
  • LG chlorine
  • the intermediate (VII) by treatment of the alcohol VI with thionyl chloride in the presence of a Base, such as pyridine, in a solvent, such as dichloromethane.
  • the compounds (VII) are then reacted in the presence of a base such as ⁇ /, ⁇ / diisopropylethylamine with primary or secondary amines YH in a solvent such as dichloromethane to give the corresponding 3-aminooxindoles (VIII) in which the linkage of the radical Y with the 3-carbon atom of the oxindole skeleton takes place via a nitrogen atom.
  • a base such as ⁇ /, ⁇ / diisopropylethylamine
  • a solvent such as dichloromethane
  • One of the preferred radicals Y is (S) -2-oxazol-2-yl-pyrrolidin-1-yl.
  • the corresponding 2- (S) -pyrrolidin-2-yl-oxazole can be prepared in the form of the HBr salt according to US 2003/0069223.
  • Y are (S) -2-oxazol-2-yl-piperidin-1-yl, (2S, 4R) -4-hydroxy-2-oxazol-2-yl-pyrrolidin-1-yl and (S) 1-oxazol-2-yl-ethylamino.
  • the HBr salt of (2S, 4R) -4-acetoxy-2-oxazol-2-yl-pyrrolidine can be prepared starting from commercially available Cbz / tert-butyl-protected (2S, 4R ) -4-hydroxyproline (Cbz-Hyp (Tbu) -OH, Bachern).
  • the oxazole ring can be closed by cyclocondensation using hexachloroethane, triphenylphosphine and triethylamine in dichloromethane.
  • the Cbz protecting group can be removed by treatment with hydrobromic acid / glacial acetic acid. Under these conditions, the terf-butyl protecting group is also cleaved and the resulting alcohol is acetylated. Under the conditions of the aldehyde release (synthesis scheme 1.B, reaction of (IX) to (X)), the deacetylation also takes place. This leads to the (2S, 4R) -4-hydroxy-2-oxazol-2-yl-pyrrolidin-1-yl compounds of the invention.
  • (S) -1-oxazol-2-yl-ethylamine can be prepared from phthalimide-protected L-alanine in three steps.
  • Phthalimide-protected L-alanine (Pht-Ala-OH) can be prepared, for example, by treatment with oxalyl chloride and catalytic amounts of N, N-dimethylformamide (DMF) in a suitable solvent (eg dichloromethane) are converted into the corresponding acid chloride (Pht-Ala-Cl).
  • DMF N, N-dimethylformamide
  • the phthalimide-protected oxazole building block can be obtained by treatment of the acid chloride with 2-trimethylsilanyl-2H- [1,2,3] triazole and heating in sulfolane. Removal of the phthalimide protecting group, for example with hydrazine hydrate in ethanol, yields the free (S) -1-oxazol-2-yl-ethylamine.
  • the resulting free hydroxy function is alkylated in a second step with an alkyl halide (eg, methyl iodide) after prior deprotonation with a strong base (eg, NaH).
  • an alkyl halide eg, methyl iodide
  • a strong base eg, NaH
  • the Cbz protecting group of the amino function is removed with a hydrobromic acid / glacial acetic acid mixture.
  • (2S, 4R) -4-TeAt-butoxy-2-oxazol-2-yl-pyrrolidine can be prepared by catalytic hydrogenation (removal of the Cbz protecting group) from (2S, 4R) -4-terf-butoxy-2-oxazole-2 -yl-pyrrolidine-1-carboxylic acid benzyl ester.
  • the HBr salt of (S) -2-methyl-2-oxazol-2-yl-pyrrolidine can be prepared starting from commercially available (S) -2-methylpyrrolidine-2-carboxylic acid (H-alpha Me-Pro-OH, Bachern).
  • the amino function is N-protected with a protecting group (e.g., Cbz) and then coupled with aminoacetaldehyde dimethyl acetal using a coupling reagent (e.g., EDCI / HOBt) in a suitable solvent (e.g., DMF).
  • a coupling reagent e.g., EDCI / HOBt
  • a suitable solvent e.g., DMF
  • the aldehyde function is released by treatment with an acid (eg, aqueous hydrochloric acid) in an organic solvent (eg, acetone).
  • the oxazole ring can be closed by cyclocondensation using hexachloroethane, triphenylphosphine and triethylamine in dichloromethane.
  • the Cbz protecting group can be removed by treatment with hydrobromic acid / glacial acetic acid.
  • the HBr salt of (2S, 4R) -4-fluoro-2-oxazol-2-yl-pyrrolidine can be prepared starting from commercially available (2S, 4R) -4-fluoropyrrolidine-2-carboxylic acid.
  • the TFA salt of (S) -3-pyrrolidin-2-yl- [1,2,4] oxadiazole can be prepared in three stages as shown in Synthetic Scheme 6 and analogously to WO2002 / 102799.
  • hydroxylamine is added to commercially available (S) -1-N-Boc-2-cyano-pyrrolidine.
  • the product obtained and trimethyl orthoformate are condensed together with acid catalysis (para-toluenesulfonic acid). Removal of the Boc protecting group with trifluoroacetic acid eventually results in the desired product.
  • the TFA salt of (S) -2-pyrrolidin-2-yl- [1, 3,4] oxadiazole can also be prepared as shown in Synthetic Scheme 6 and analogously to WO2002 / 102799 in three steps.
  • a first step commercially available Boc-Pro-OMe is reacted with hydrazine to give the corresponding hydrazide.
  • a second step the resulting hydrazide is condensed with trimethyl orthoformate under acid catalysis (p-TsOH). Removal of the Boc protecting group with trifluoroacetic acid results in the desired product.
  • the HBr salt of 4-methyl-2- (S) -pyrrolidin-2-yl-oxazole can be prepared from commercially available Cbz-Pro-OH, as shown in Synthetic Scheme 7.
  • the protected amino acid is treated with 2-amino-propan-1-ol using a coupling reagent such as N- (3-dimethylaminopropyl) -N'-ethyl-carbodiimide hydrochloride (EDCI) in the presence of 1-hydroxy- benzotriazole, coupled in a solvent such as DMF.
  • EDCI N- (3-dimethylaminopropyl) -N'-ethyl-carbodiimide hydrochloride
  • the aldehyde function can be generated by oxidation with the Dess-Martin reagent or according to Swern (J. Org. Chem. 43, 2480 (1978)).
  • the oxazole ring can be closed by cyclocondensation using hexachloroethane, triphenylphosphine and triethylamine in dichloromethane.
  • the Cbz protecting group can be removed by treatment with hydrobromic acid / glacial acetic acid.
  • the HBr salt of 5-methyl-2- (S) -pyrrolidin-2-yl-oxazole can be prepared starting from commercially available Cbz-Pro-OH (Synthetic Scheme 8).
  • the protected amino acid is coupled with 1-amino-propan-2-ol using a coupling reagent (e.g., EDCI / HOBt) in a suitable solvent (e.g., DMF).
  • a coupling reagent e.g., EDCI / HOBt
  • a suitable solvent e.g., DMF
  • the aldehyde function can be generated by oxidation with the Dess-Martin reagent or according to Swern (J. Org. Chem. 43, 2480 (1978)).
  • the oxazole ring can be closed by cyclocondensation using hexachloroethane, triphenylphosphine and triethylamine in dichloromethane. Finally, the Cbz protecting group can be removed by treatment with hydrobromic acid / glacial acetic acid.
  • the compounds (VIII), (IX), (X) and (XI) can be obtained as a mixture of diastereomers.
  • a separation of the two diastereomers for example, in the case of (VIII) and (X) by chromatography on silica gel using a suitable eluent, for example ethyl acetate in dichloromethane or methanol in dichloromethane.
  • a suitable eluent for example ethyl acetate in dichloromethane or methanol in dichloromethane.
  • the compounds (VIII), (IX) and (X) were processed as diastereomerically pure compounds.
  • the diastereomers can in many cases be purified by chromatographic methods, for example over silica gel using a suitable eluent, such as methanol in dichloromethane, or by preparative HPLC using a suitable solvent Eluent, such as acetonitrile in water with small amounts of trifluoroacetic acid, are separated.
  • a suitable eluent such as methanol in dichloromethane
  • a suitable solvent Eluent such as acetonitrile in water with small amounts of trifluoroacetic acid
  • the 3-hydroxy-oxindoles (XII) can be prepared by addition of lithium-organic or Grignard compounds to the 3-keto group of the substituted isatin (V).
  • R A 1 1 OCH 3
  • PG suitable protecting group PG, such as triisopropylsilyl
  • organolithium reagents such as n-butyllithium
  • the phenolic oxygen function can be alkylated with alkyl halides containing substituted amino groups R A 2 , eg by heating the phenol (XVI) with the alkylating agents R A 2 - (C 2 -C 3 alkyl) -CI in DMF in the presence of a base such as potassium carbonate in the microwave.
  • a base such as potassium carbonate in the microwave.
  • the resulting Grignard solution was added to an ice-cooled solution of the 5-chloroisatin sodium salt [prepared by treating a solution of 5-chloroisatin (13.1 g, 72 mmol) in THF (400 mL) with a
  • the following compounds 3 to 43 were prepared in diastereomerically pure form.
  • the compounds were purified by preparative reversed-phase HPLC (mobile phase: gradient of 10% to 80% acetonitrile in water, 0.1% trifluoroacetic acid or 0.2% acetic acid as modulator) and, if they contain a basic nitrogen in the molecule, as Trifluoroacetic acid salts or acetic acid salts.
  • Example 12 3- (5-Azetidin-1-ylmethyl-2-methoxy-phenyl) -5-chloro-1- (4-methoxy-benzenesulfonyl) -3 - ((S) -2-oxazol-2-yl-pyrrolidine-1 -yl) -1,3-dihydroindol-2-one,
  • the compounds of the invention are antagonists of the so-called receptors of the vasopressin / oxytocin family. Such compounds can be tested in suitable assays that detect affinity for a receptor, the affinity constant Ki being a measure of the potency of the compounds and a smaller value represents a greater potency.
  • the compounds of the invention were tested for their affinity for the V1b receptor in the following receptor binding assay.
  • test substances were dissolved in a concentration of 10 -2 M in DMSO and further diluted in DMSO to 5x10 "4 M to 5x10" 9 M.
  • This DMSO DMSO
  • CHO-K1 cells stably expressed with human vasopressin V1 b receptor were harvested and homogenized in 50 mM Tris-HCl and in the presence of protease inhibitors (Roche complete Mini # 1836170) with a Polytron Homogenizer at medium position 2x10 seconds and then 1 h Centrifuged at 40,000 xg. The membrane pellet was again homogenized as described and centrifuged and then taken up in 50 mM Tris-HCl, pH 7.4, homogenized and stored in aliquots frozen at -190 0 C in liquid nitrogen.
  • protease inhibitors Roche complete Mini # 1836170
  • the binding test was performed according to the method of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).
  • Incubation buffer was: 50mM Tris, 10mM MgCl 2 , 0.1% BSA, pH 7.4.
  • membranes 50 ⁇ g / ml protein in
  • Binding was determined with 1 ⁇ M AVP (Bachern # H1780). All determinations were made in triplicate. After incubation (60 minutes at room temperature), the free radioligand was filtered by vacuum filtration (Skatron cell harvester 7000) over Wathman GF / B glass fiber filter mats and the filters transferred to scintillation vials. The
  • Liquid scintillation measurement was carried out in a Tricarb Model 2000 or 2200CA (Packard). The conversion of the measured cpm into dpm was carried out using a standard quench series.
  • the binding parameters were calculated by nonlinear regression in SAS.
  • the algorithms of the program work analogously to the LIGAND evaluation program (Munson PJ and Rodbard D, Analytical Biochem. 239 (1980)).
  • the Kd value of 3 H-AVP to the recombinant hV2 receptors is 0.4 nM and was used to determine the Ki value.
  • the affinities for the human vasopressin receptor V1b were measured in accordance with the above test and the affinity constants (Ki) were determined.
  • Table 1 below shows the V1 b receptor affinity of selected compounds (+++ means ⁇ 10 nM, ++ means 10-100 nM and + means 100-1000 nM).
  • the indicated affinities for the V1 b receptor refer to the diastereomer, which has a stronger affinity (lower Ki value) for the V1 b receptor.
  • affinities for other vasopressin receptors or their subtypes e.g. V1a and V2, and the oxytocin (OT) receptor.
  • the available quotients of the corresponding Ki values ie
  • Ki (V1a) / Ki (V1b) can be used as a measure of a possible selectivity the compounds of the invention with respect to a particular vasopressin or oxytocin receptor serve.
  • Vasopressin V1a receptor binding test
  • test substances were dissolved in a concentration of 10 -2 M in DMSO.
  • concentration of 10 -2 M in DMSO was carried out in incubation buffer (50 mM Tris, 10 mM MgCl 2 , 0.1% BSA, pH 7.4).
  • CHO-K1 cells stably expressed with human vasopressin V1a receptor 100
  • Binding test The binding test was carried out in accordance with the method of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).
  • Incubation buffer was: 50mM Tris, 10mM MgCl 2 , 0.1% BSA, pH 7.4.
  • membranes (20 ⁇ g / ml protein in incubation buffer) of CHO-K1 cells with stably expressed human V1a receptors (cell line hV1 a_5_CHO) were incubated with 0.04 nM 125 I-AVP (8 ⁇ g / ml).
  • Vasopressin NEX 1278 in incubation buffer (50 mM Tris, 10 mM MgCl 2 , 0.1% BSA, pH 7.4) (total binding) or additionally incubated with increasing concentrations of test substance (displacement experiment). Non-specific binding was determined with 1 ⁇ M AVP (Bachern # H1780). Triple determinations were made.
  • the free radioligand was filtered by vacuum filtration (Skatron cell harvester 7000) over Wathman GF / B glass fiber filter mats and the filters transferred to scintillation vials.
  • the liquid scintillation measurement was carried out in a Tricarb Model 2000 or 2200CA (Packard). The conversion of the measured cpm into dpm was carried out using a standard quench series.
  • Receptors were determined in saturation experiments. A Kd value of 1.33 nM was used to determine the Ki value.
  • test substances were dissolved in a concentration of 10 -2 M in DMSO. Further dilution of this DMSO solution was carried out in incubation buffer (50 mM Tris, 10 mM MgCl 2 , 0.1% BSA, pH 7.4).
  • CHO-K1 cells stably expressed with human vasopressin V2 receptor (clone 23) were harvested and homogenized in 50 mM Tris-HCl and in the presence of protease inhibitors (Roche complete Mini # 1836170) with a Polytron homogenizer at medium position 2x10 seconds and then for 1 h Centrifuged at 40,000 xg. The membrane pellet was again homogenized as described and centrifuged and then taken up in 50 mM Tris-HCl, pH 7.4, homogenized and stored in aliquots frozen at -190 0 C in liquid nitrogen.
  • the binding test was performed according to the method of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).
  • Incubation buffer was: 50mM Tris, 10mM MgCl 2 , 0.1% BSA, pH 7.4.
  • membranes 50 ⁇ g / ml protein in incubation buffer
  • CHO-K1 cells with stably expressed human V2 receptors (cell line hV2_23_CHO) with 1-2 nM 3 H-AVP (8-Arg vasopressin, Perkin Elmer # 18479) in incubation buffer (50 mM Tris, 10 mM MgCl 2 , 0.1% BSA, pH 7.4) (total binding) or in addition with increasing
  • test substance concentration experiment
  • Non-specific binding was determined with 1 ⁇ M AVP (Bachern # H1780). Triple determinations were made. 102
  • the free radioligand was filtered by vacuum filtration (Skatron cell harvester 7000) over Wathman GF / B glass fiber filter mats and the filters transferred to scintillation vials.
  • the liquid scintillation measurement was carried out in a Tricarb Model 2000 or 2200CA (Packard). The conversion of the measured cpm into dpm was carried out using a standard quench series.
  • the binding parameters were calculated by nonlinear regression in SAS.
  • the algorithms of the program work analogously to the LIGAND evaluation program (Munson PJ and Rodbard D, Analytical Biochem., 107, 220-239 (1980)).
  • the Kd value of 3 H-AVP to the recombinant hV2 receptors is 2.4 nM and was used to determine the Ki value.
  • the substances were dissolved in a concentration of 10 "2 MM in DMSO and diluted with incubation buffer (50 mM Tris, 10 mM MgCl 2, 0.1% BSA, pH 7.4).
  • Confluent HEK-293 cells with transiently expressed recombinant human oxytocin receptors were centrifuged at 750 xg for 5 minutes at room temperature. The residue was taken up in ice-cold lysis buffer (50 mM Tris-HCl, 10% glycerol, pH 7.4 and Roche Complete protease inhibitor) and subjected to 20 minutes at 4 0 C to osmotic shock. Thereafter, the lysed cells were centrifuged at 750 for 20 minutes at 4 0 C, the residue taken up in incubation buffer, and aliquots of 10 7 cells / ml. The aliquots were up to the 103
  • the binding parameters were calculated by nonlinear regression analysis (SAS), analogous to the program LIGAND by Munson and Rodbard (Analytical Biochem 1980, 107: 220-239).
  • SAS nonlinear regression analysis
  • the Kd value of 3 H-oxytocin to the recombinant hOT receptors is 7.6 nM and was used to determine the Ki value.
  • the metabolic stability of the compounds of the invention was determined in the following test.
  • test substances are incubated in a concentration of 0.5 ⁇ M as follows:
  • Potassium phosphate buffer pH 7.4 preincubated at 37 ° C for 5 min.
  • the start of the reaction is carried out by the addition of NADPH (1 mg / ml). After 0, 5, 10, 15, 20 and 30 min, aliquots are removed and the reaction is stopped with the same volume of acetonitrile and cooled down. The samples are frozen until analysis.
  • the half life of the compound can be calculated assuming a first order kinetics from the decrease in the concentration of the compound over time.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des dérivés d'oxindole de formule (I), dans laquelle les substituants R1, R2, A, B et Y sont tels que définis à la revendication 1. La présente invention porte également sur des médicaments contenant ces dérivés et sur leur utilisation pour la prophylaxie et/ou le traitement de maladies associées à la vasopressine.
EP06819882A 2005-12-02 2006-12-01 Derive d'oxindole substitues, medicaments les contenant et leur utilisation Withdrawn EP1957480A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74206505P 2005-12-02 2005-12-02
DE102005059484 2005-12-02
PCT/EP2006/069180 WO2007063123A1 (fr) 2005-12-02 2006-12-01 Derives d'oxindole substitues, medicaments les contenant et leur utilisation

Publications (1)

Publication Number Publication Date
EP1957480A1 true EP1957480A1 (fr) 2008-08-20

Family

ID=40198306

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06819882A Withdrawn EP1957480A1 (fr) 2005-12-02 2006-12-01 Derive d'oxindole substitues, medicaments les contenant et leur utilisation

Country Status (5)

Country Link
US (3) US8044079B2 (fr)
EP (1) EP1957480A1 (fr)
JP (1) JP2009517444A (fr)
CN (1) CN101336239A (fr)
WO (1) WO2007063123A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2227463B1 (fr) * 2007-12-27 2016-08-17 AbbVie Deutschland GmbH & Co KG Dérivés substitués d'oxindole et leur utilisation pour le traitement de maladies dépendant de la vasopressine
EP4146192A1 (fr) * 2020-05-05 2023-03-15 The Scripps Research Institute Méthodes et compositions pour le traitement du sars-cov 2

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663431A (en) 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
FR2714378B1 (fr) * 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2804114B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2804115B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2805536B1 (fr) 2000-02-25 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
US6673790B1 (en) 2000-04-03 2004-01-06 Sanofi-Synthelabo Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
FR2807038B1 (fr) * 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
FR2810320B1 (fr) 2000-06-19 2002-08-23 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2827604B1 (fr) * 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
WO2005021534A1 (fr) 2003-08-28 2005-03-10 Taisho Pharmaceutical Co., Ltd. Dérivé de 1,3-dihydro-2h-indol-2-one
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
MX2007011693A (es) * 2005-03-24 2008-03-11 Abbott Gmbh & Co Kg Derivados de oxindoles sustituidos, farmacos que contienen dichos derivados y uso de los mismos.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007063123A1 *

Also Published As

Publication number Publication date
US8044079B2 (en) 2011-10-25
US20150218146A1 (en) 2015-08-06
US20100273766A1 (en) 2010-10-28
US9006276B2 (en) 2015-04-14
JP2009517444A (ja) 2009-04-30
CN101336239A (zh) 2008-12-31
US20130029966A1 (en) 2013-01-31
WO2007063123A1 (fr) 2007-06-07

Similar Documents

Publication Publication Date Title
US7803834B2 (en) Substituted oxindole derivatives, drugs containing said derivatives and the use thereof
DE69830403T2 (de) Inhibitoren des faktors xa mit einer neutralen gruppe mit p1-spezifität
DE69736642T2 (de) Heterocyclische Verbindungen, ihre Herstellung und Verwendung
EP1487821B1 (fr) Piperidines substituees par benzodiazepine a utiliser dans le traitement de maladies cardiovasculaires
US20120115842A1 (en) Substituted Oxindole Derivatives, Medicaments Containing Said Derivatives and Use Thereof
DE102005014904A1 (de) Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
TWI403508B (zh) 經取代苯并咪唑酮衍生物、包含其之醫藥品及其用途
WO2006038738A1 (fr) Agent de régulation du fonctionnement d'un récepteur
DE102005014936A1 (de) Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
DE10237722A1 (de) Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
JP2011516599A (ja) ニコチン性アセチルコリン受容体サブタイプα７のモジュレーターとしてのインドール類
US8431567B2 (en) Substituted oxindole derivatives and their use as vasopressin and/or oxytocin receptor ligands
JP2011510030A (ja) 置換アミノ−ベンゾイミダゾール類、該化合物を含む医薬、これらの使用及びこれらの製造方法
EP1957480A1 (fr) Derive d'oxindole substitues, medicaments les contenant et leur utilisation
WO2012022120A1 (fr) Composé dihydro-pyrazole
EP3947360B1 (fr) Composés inhibiteurs de la sérotonine 5-ht2b
DE102005015957A1 (de) Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
DE19945787A1 (de) Arylsulfonamid-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102005014628A1 (de) Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080601

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LUBISCH, WILFRIED

Inventor name: UNGER, LILIANE

Inventor name: OOST, THORSTEN

Inventor name: NETZ, ASTRID

Inventor name: HORNBERGER, WILFRIED

Inventor name: WERNET, WOLFGANG

Inventor name: GENESTE, HERVE

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1118825

Country of ref document: HK

17Q First examination report despatched

Effective date: 20090320

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111113

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1118825

Country of ref document: HK